Last Update 10 Mar 26

Fair value Decreased 3.82%

OGN: Refreshed Earnings Assumptions And M&A Interest Will Support Future Repricing

Analysts have trimmed their fair value estimate for Organon to $9.00, while Barclays lifted its price target to $8.00 from $7.50 after updating its model following the Q4 report, prompting a reassessment of growth, margins and future P/E assumptions in our narrative update.

Analyst Commentary

Recent Street research reflects a cautious stance on Organon, even as some price targets are adjusted following the Q4 update. The latest move to an $8.00 target, together with an Underweight rating, indicates that analysts see some value support but still question the balance of risk and reward at current levels.

Bullish Takeaways

Bullish analysts view the lift in the target to $8.00 as a sign that recent information from the Q4 report has helped firm up assumptions around earnings power and P/E potential.
The updated models incorporate fresh data, which some see as tightening the valuation range and reducing uncertainty around forward estimates.
The revised fair value work suggests that, at lower price levels, there may be room for upside if the company executes in line with the refreshed margin and growth assumptions.
Raising the target, even modestly, indicates that the downside case has been reassessed and, for some, appears less severe than previously embedded in their models.

Bearish Takeaways

Bearish analysts maintain an Underweight rating, reflecting ongoing concerns about the balance between Organon’s execution risks and the current market valuation.
The cautious stance suggests that, while models have been updated, there is still hesitation around the company’s ability to deliver on growth and margin assumptions embedded in these forecasts.
The relatively low absolute target of $8.00, compared with higher fair value estimates from other sources such as the trimmed $9.00 level, indicates that some remain conservative on the appropriate P/E multiple.
Retaining an Underweight view after the Q4 report points to continued skepticism that current fundamentals fully support a more constructive rating or higher valuation range.

What's in the News

Sun Pharmaceutical Industries submitted a nonbinding, all cash offer to acquire Organon, reportedly backed by US$10b to US$14b in bridge financing from global banks, with due diligence expected to start before any binding bid is made (M&A rumors and discussions).
Organon issued full year 2026 guidance, indicating it expects revenue of approximately US$6.2b for the year (corporate guidance).
The US Food and Drug Administration approved a supplemental New Drug Application for NEXPLANON, extending its labeled duration of use to 5 years and requiring a Risk Evaluation and Mitigation Strategy, with product access in the US to be controlled through the NEXPLANON REMS program starting 23 February 2026 (product related announcement).
Organon plans to present pooled Phase 3 ADORING trial data for VTAMA cream in pediatric atopic dermatitis at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting, highlighting early and consistent improvements in patient and family sleep related outcomes across multiple age groups (product related announcement).
Organon signed an agreement with Daiichi Sankyo Europe to commercialize Nilemdo, a first in class cholesterol lowering therapy for patients who are not well served by statins, in France, Denmark, Iceland, Sweden, Finland and Norway (client announcement).

Valuation Changes

Fair Value was trimmed slightly, with the estimate moving from $9.36 to $9.00.
The Discount Rate was raised from 9.80% to 10.71%, indicating a higher required return in the updated model.
Revenue Growth was adjusted from 4.13% to 71.06%, reflecting a major change in assumptions for top-line expansion.
The Net Profit Margin was kept broadly stable, moving modestly from 13.35% to 13.42% in the updated assumptions.
The future P/E was reduced slightly from 3.91x to 3.74x, implying a marginally lower valuation multiple applied to earnings.

30 views

Key Takeaways

New product launches and biosimilars adoption are driving market share growth, while portfolio shifts and operational efficiencies support stronger margins.
Expanding presence in global and emerging markets, together with improving financial flexibility, positions the company for sustained revenue growth and strategic investments.
Heavy reliance on legacy products, policy and pricing headwinds, weak pipeline innovation, and high restructuring costs threaten stability, growth, and profit margins amid intensifying competition.

Catalysts

About Organon

Develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally.What are the underlying business or industry changes driving this perspective?

New product launches and expanded indications-especially the launch of Vtama (including approved pediatric use and expanded access) and the upcoming 5-year Nexplanon indication-position Organon to capture additional market share and drive future revenue growth, leveraging global demographic shifts toward increased healthcare demand.
Strength in global markets, with double-digit growth for Nexplanon and fertility products ex-U.S., capitalizes on rising healthcare access in emerging economies, supporting a higher long-term growth trajectory for revenues.
The biosimilars portfolio is outperforming expectations, underpinned by accelerating adoption (e.g., Hadlima's growth, new launches like Tofidence, and a strong pipeline including Henlius denosumab), providing a sustainable pathway to top-line expansion while benefiting from industry-wide momentum toward biosimilars as key biologics lose exclusivity.
Margin expansion catalysts include operational efficiencies from restructuring and supply chain optimization, as well as a shift in portfolio mix toward higher gross margin assets (Vtama, biosimilars, new fertility products), supporting long-term improvement in EBITDA margin and net earnings.
The company's continued debt reduction and strong free cash flow generation enhance financial flexibility, enabling further pipeline investments and M&A opportunities, both of which can accelerate long-term earnings growth and mitigate risks from patent cliffs or single-segment concentration.

Organon Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Organon's revenue will grow by 1.2% annually over the next 3 years.
Analysts assume that profit margins will increase from 11.1% today to 15.2% in 3 years time.
Analysts expect earnings to reach $990.3 million (and earnings per share of $3.76) by about September 2028, up from $700.0 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 4.7x on those 2028 earnings, up from 3.9x today. This future PE is lower than the current PE for the US Pharmaceuticals industry at 19.0x.
Analysts expect the number of shares outstanding to grow by 0.94% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 9.44%, as per the Simply Wall St company report.

Organon Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Organon's revenue remains heavily exposed to mature, off-patent products, as highlighted by the significant impact of loss of exclusivity (LOE) on Atozet in Europe and ongoing pricing pressure across legacy brands like NuvaRing and Dulera; this persistent vulnerability to generic competition poses a structural risk to long-term revenue stability and growth.
The Women's Health franchise-particularly Nexplanon-is facing near-term and potentially persistent headwinds in the U.S. due to federal and state funding uncertainties for subsidized contraception, with management noting market confusion and hesitancy around Planned Parenthood and Medicaid issues, which could pressure domestic revenue growth if policy volatility persists or worsens.
Organon's pipeline-driven growth prospects may be overstated given their recent discontinuation of internal R&D programs (e.g., the endometriosis candidate 6219 and its backup asset); this confirms company dependence on business development rather than organic innovation, raising concerns about the sustainability of new product flows and future earnings momentum compared to more robustly innovative peers.
The path to increased profitability is reliant on continued cost optimization, restructuring, and realization of operational efficiencies-however, restructuring and manufacturing transition expenses are still significant and gross margin improvement is not expected until 2027, which could act as a drag on net margins in the medium term if execution falters or savings are delayed.
Increasing global pricing pressure, mandatory price revisions in international markets, and the ongoing shift to biosimilars-evident in both Organon's own biosimilar strategy and competitive market realities-threaten overall pricing power and gross margins, risking further erosion of earnings if these trends accelerate or if newly launched biosimilars face heightened competition from larger, better-capitalized rivals.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $13.167 for Organon based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $18.0, and the most bearish reporting a price target of just $9.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $6.5 billion, earnings will come to $990.3 million, and it would be trading on a PE ratio of 4.7x, assuming you use a discount rate of 9.4%.
Given the current share price of $10.37, the analyst price target of $13.17 is 21.2% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Organon?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Leadership Changes And Regulatory Concerns Will Shape Near-Term Market Prospects